By Colin Kellaher
Bristol Myers Squibb said a key European regulatory committee is backing a formulation of its blockbuster cancer drug Opdivo that can be injected under the skin.
Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of a subcutaneous formulation of Opdivo across multiple previously approved adult solid tumors as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy combination therapy, or in combination with chemotherapy or cabozantinib.
The Princeton, N.J., biopharmaceutical company said the European Commission, which generally follows CHMP's advice, will now review the recommendation, with a decision expected by June 2.
Opdivo, which harnesses the body's own immune system to fight cancer and generated more than $9.3 billion in revenue last year, is currently administered intravenously in Europe.
The U.S. Food and Drug Administration approved the subcutaneous formulation of Opdivo late last year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 28, 2025 08:34 ET (12:34 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。